

The anticancer effects of the vitamin E isoform, γ- tocotrienol, and vitamin D3 act synergistically to inhibit MDA-MB-231 triple negative breast cancer (TNBC) cell proliferation and viability *in vitro*.

Mohammed Rafi Anwar, and Paul W. Sylvester

School of Basic Pharmaceutical & Toxicological Sciences University of Louisiana at Monroe

• Introduction and Background:

- **Triple Negative Breast Cancer:** Triple negative breast cancer (TNBC) is the most difficult type of breast cancer to treat among all breast cancer subtypes. MDA-MB-231 was the TNBC cell line use in these studies.
- **Problems with the Conventional Therapies:** Generation of side effects, drug resistance after prolonged treatment, as well as relapse and disease progression.
- **Natural Product Based Therapy:** Natural products are an important source of therapies. In the period of 1981 to 2014 the FDA approved 1,562 drugs, which 38% were natural products or their derivatives.
- **Benefits of Combined therapy:** There are many benefits in use of combination therapy. Often times each drug can be used at a lower dose and results in less side effects and enhance efficacy, as well as having a lower probability of drug resistance.
- Background Information of γ-Tocotrienol: It is a Natural form of Vitamin E. It is found in palm oil and other natural resources. Studies showed high dietary intake of palm oil suppressed carcinogen induced mammary tumor growth. γ-Tocotrienol is responsible for the suppression of various types of cancer signaling pathways in many types of breast cancer like: PI3K/Akt/mTOR, MAPK, and so on.
- **Background Information of Vitamin D3:** Vitamin D is acquired through both sun exposure and dietary sources. $1\alpha, 25(OH)2D3$, the active form of vitamin D. It is found in any many studies that $1\alpha, 25(OH)2D3$ has potential anticarcinogenic effects, including regulation of cell growth and proliferation, stimulation of apoptosis, and down-regulation of estrogen receptors.

• <u>Hypothesis:</u>

- Combination of γ -Tocotrienol and Vitamin D3 may show a synergistic anticancer effects against MDA-MB-231 TNBC cells.
- <u>Aims:</u>

1. To determine the anti-proliferative dose of γ -tocotrienol and Vitamin D3 on MDA-MB-231 cell line. 2. To determine the anti-colony formation effects of the combined doses by colony formation assay. 3. To determine the anti-invasiveness and migratory effects of the combined doses by Matrigel invasion and scratch wound healing assay. 4. To determine the effect of combined effect on cell cycle by flow cytometry 5. To determine the effect of combined effect on apoptosis by flow cytometry 6. To determine the effect combined dose on p-MAPK, and other cell cycle-apoptosis markers by western blotting.

Methods and Results: Cell Viability Assay & Colony Formation Assay




Fig: Effects of various doses of Vitamin D_3 treatment alone or in combination with 8 μ M (subeffective dose) γ -Tocotrienol on growth of human MDA-MB-231 cells.




Fig: Effects of untreated control, 8 μ M γ -tocotrienol, 10nM vitamin D3, and combined treatment of 8 μ M γ -tocotrienol and 10nM vitamin D3 on clonogenicity of MDA-MB-231 cells as detected by colony formation assay.

Effects of Mono and Combined Therapy on Invasion and Migration




Fig: Effects of untreated control (C), 8 μ M γ -tocotrienol (γ T3), 10nM vitamin D3 (D3) and combined 8 μ M γ -tocotrienol and 10nM vitamin D3 (γ T3+D3) treatments on invasiveness and migration of MDA-MB-231 cells as detected by matrigel invasion assay and scratch would healing assay.

Cell Cycle and Apoptosis Analysis with Flow Cytometry




Fig: Percent of cells in G0/G1 phase of cell cycle following a 4-day treatment with 8 μ M γ -tocotrienol (γ T3), 10 nM vitamin D3 (D3) or the combination of γ T3+D3 as compared to vehicle treated control cells (C).

Fig: Annexin V positive staining in MDA-MB-231 cells following a 4-days treatment with 8 μ M γ -tocotrienol (γ T3) and 10 nM vitamin D3 (D3) as compared to untreated group.

Combinational Treatment of γ-Tocotrienol and Vitamin D3 Causes Downregulation of p-MAPK and Apoptotic Marker




Fig: I Effects of untreated control (C), 8 μ M γ -tocotrienol (γ T3), 10nM vitamin D3 (D3) and combined 8 μ M γ -tocotrienol and 10nM vitamin D3 (γ T3+D3) treatments on p-MAPK and cleaved caspase-3 levels as indicated by their integrated optical density (arbitrary units) normalized to their respective corresponding total protein levels in each well.

Combinational Treatment of γ-Tocotrienol and Vitamin D3 Causes Downregulation of Cell Cycle Markers





Fig:Effects of untreated control (C), 8 μ M γ -tocotrienol (γ T3), 10nM vitamin D3 (D3) and combined 8 μ M γ -tocotrienol and 10nM vitamin D3 (γ T3+D3) treatments on CDK4 and CDK6 levels as indicated by their integrated optical density (arbitrary units) normalized to their respective corresponding total protein levels in each well.

Conclusion and Acknowledgement

- Combined treatment with γ -tocotrienol and vitamin D3 induces a synergistic antiproliferative, anti-metastatic and apoptotic effects in MDA-MB-231 TNBC cells.
- The antiproliferative effects induced by this combined treatment was associated with a significant increase in Go/G1 cell cycle arrest as evidence by a reduction in CDK4, CDK6, and phosphorylated ERK1/2 (active form) mitogenic signaling.
- The anti-metastatic effects induced by this combined treatment γ -tocotrienol and vitamin D3 was evidenced by a significant increase in apoptosis as evidenced by elevations in positive Annexin V staining and increased levels of cleaved caspase-3.
- In summary, these findings strongly suggest that combined γ-tocotrienol and vitamin D3 therapy may provide significant benefits in the treatment of women with triple negative breast cancer.



• Acknowledgement:

This study is supported by Louisiana Cancer Foundation.